Compare Becton Dickinson and Co (BDX) vs Norfolk Southern Corporation (NSC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Norfolk Southern Corporation — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Norfolk Southern Corporation trades at $325.89 (market cap $73.40B). The key difference: Norfolk Southern Corporation is the larger of the two by market cap, and Becton Dickinson and Co pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| BDX | NSC | |
|---|---|---|
Market Cap | $41.51B | $73.40B |
Sector | Health | Technology |
52-Week High | $185.39 | $327.59 |
52-Week Low | $135.49 | $259.49 |
Enterprise Value | $57.97B | $89.16B |
Dividend Yield | 2.79% | 1.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Norfolk Southern (NSC) trades at $327.59, up 0.04% on the day, with a bullish technical outlook driven by moving averages and a consensus price target of $344.40. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected on July 23, 2026. Strong profitability is evident with a 21.91% net income margin and 17.6% ROE, though valuation multiples like a P/E of 27.53 are elevated. Recent news highlights the ongoing merger review with Union Pacific, a key regulatory focus.
NSC offers steady earnings growth and dividend income, but risks include regulatory hurdles for the merger and rich valuations limiting near-term upside. Analyst sentiment is mixed with 44% buy ratings, suggesting cautious optimism amid merger uncertainty. The stock's proximity to its 52-week high warrants monitoring for pullbacks to support levels near $323.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →
